Skip to main content
SpringerLink
Log in

Antimalarials

  • Chapter
Cutaneous Lupus Erythematosus

  • 906 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • American College of Rheumatology Ad Hoc Committee on Clinical Guidelines (1996) Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 39:723–731

    Google Scholar 

  • Araiza-Casillas R, Cardenas F, Morales Y, Cardiel MH (2004) Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus 13:119–124

    Article  PubMed  Google Scholar 

  • Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, Papo T, Schaeffer A, Bierling P, Godeau B (2002) Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 29:75–83

    PubMed  Google Scholar 

  • Asch PH, Caussade P, Marquart-Elbaz C, Boehm N, Grosshans E (1997) Chloroquine-induced achromotrichia. An ultrastructural study. Ann Dermatol Venereol 124:552–556

    PubMed  Google Scholar 

  • Avina-Zubieta JA, Galindo-Rodriguez S, Newman S, Suarez-Almazor ME, Russell AS (1998) Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis 57: 582–587

    PubMed  Google Scholar 

  • Baguet JP, Tremel F, Fabre M (1999) Chloroquine cardiomyopathy with conduction disorders. Heart 81:221–223

    PubMed  Google Scholar 

  • Barthel HR, Meier LG, Wallace DJ (1996) Antimalariamittel bei rheumatischen Erkrankungen. Dtsch med Wschr 121:1576–1582

    PubMed  Google Scholar 

  • Bauer F (1981) Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis). Its early and late sequelae and its malignant potential. A review. J Am Acad Dermatol 4:239–248

    PubMed  Google Scholar 

  • Becerra-Cunat JL, Coll-Canti J, Gelpi-Mantius E, Ferrer-Avelli X, Lozano-Sanchez M, Millan-Torne M, Ojanguren I, Ariza A, Olive A (2003) Chloroquine-induced myopathy and neuropathy: progressive tetraparesis with areflexia that simulates a polyradiculoneuropathy. Two case reports. Rev Neurol 36:523–526

    PubMed  Google Scholar 

  • Benagiano G (2001) Non-surgical female sterilization with quinacrine: an update. Contraception 63:239–245

    Article  PubMed  Google Scholar 

  • Bienfang D, Coblyn JS, Liang MH, Corzillius M (2000) Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. J Rheumatol 27:2703–2706

    PubMed  Google Scholar 

  • Boelaert JR, Piette J, Sperber K (2001) The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol 20:137–140

    Article  PubMed  Google Scholar 

  • Borba EF, Bonfa E (2001) Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28:780–785

    PubMed  Google Scholar 

  • Borden MB, Parke AL (2001) Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. Drug Saf 24:1055–1063

    PubMed  Google Scholar 

  • Callaway JL (1979) Late sequelae of quinacrine dermatitis, a new premalignant entity. J Am Acad Dermatol 1:456–457

    PubMed  Google Scholar 

  • Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. New Engl J Med 324:150–154

    Google Scholar 

  • Canadian rheumatology association (2000) Canadian Consensus Conference on hydroxychloroquine. J Rheumatol 27:2919–2921

    Google Scholar 

  • Carmichael SJ, Charles B, Tett SE (2003) Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit 25:671–681

    Article  PubMed  Google Scholar 

  • Chung HS, Hann SK (1997) Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine. J Dermatol 24:569–572

    PubMed  Google Scholar 

  • Clegg DO, Dietz F, Duffy J, Willkens RF, Hurd E, Germain BF, Wall B, Wallace DJ, Bell CL, Sleckman J (1997) Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine. J Rheumatol 24:1896–1902

    PubMed  Google Scholar 

  • Clemessy JL, Taboulet P, Hoffmann JF, Hantson P, Barriot P, Bismuth C, Baud J (1996) Treatment of acute chloroquine poisoning: a 5-year experience. Critical Care Med 24:1189–1195

    Article  Google Scholar 

  • Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong du LT, Sebbough D, Wechsler B, Vauthier D, Denjoy I, Lupoglazoff JM, Piette JC (2003) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a controll group. Arthritis Rheum 48:3207–3211

    Article  PubMed  Google Scholar 

  • D’Cruz D (2001) Antimalarial therapy: a panacea for mild lupus? Lupus 10:148–151

    Article  PubMed  Google Scholar 

  • Dereure O, Guilhou JJ (2002) Eosinophilic-like erythema: a clinical subset of Well’s eosinophilic cellulitis responding to antimalarial drugs? Ann Dermatol Venereol 129:720–723

    PubMed  Google Scholar 

  • Dubois EL (1976) Lupus erythematosus, 2nd edn. University of Southern California Press, Los Angeles, pp 548, 588

    Google Scholar 

  • Ducharme J, Farinotti R (1996) Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokin 31:257–274

    Google Scholar 

  • Dutz JP, Ho VC (1998) Immunosuppressive agents in dermatology: an update. Dermatol Clin 16:235–251

    Article  PubMed  Google Scholar 

  • Easterbrook M (1985) The sensitivity of Amsler grid testing in early chloroquine retinopathy. Trans Opthalmol Soc UK 104:204–207

    Google Scholar 

  • Engel GL, Romano J, Ferris Eb (1947) Effect of quinacrine on the central nervous system. Arch Neurol 58:337–350

    Google Scholar 

  • Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD (2002) A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 41:924–929

    Article  PubMed  Google Scholar 

  • Espinola RG, Pierangeli SS, Ghara AE, Harris EN (2002) Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 87:518–522

    PubMed  Google Scholar 

  • Feldmann R, Salomon D, Saurat JH (1994) The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 189:425–427

    PubMed  Google Scholar 

  • Ferrante A, Rowan-Kelly B, Seow WK, Thong YH (1986) Depression of human polymorphonuclear leucocyte function by anti-malarial drugs. Immunology 85:125–130

    Google Scholar 

  • Fox RI, Dixon R, Guarrassi V, Krubel S (1996) Treatment of primary Sjogren’s syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5(Suppl 6):S31–S36

    PubMed  Google Scholar 

  • Fries JF, Williams CA, Ramey DR, Block DA (1993) The relative toxicity of the disease-modifying antirheumatic drugs. Arthritis Rheum 36:297–306

    PubMed  Google Scholar 

  • Humphreys F, Mrks JM (1988) Mepacrine and pregnancy. Br J Dermatol 118:452

    PubMed  Google Scholar 

  • Jancinova V, Nosal R, Drabikova K, Danihelovaa E (2001) Cooperation of chloroquine and blood platelets in inhibition of polymorphonuclear leukocyte chemiluminescence. Biochem Pharmacol 62:1629–636

    Article  PubMed  Google Scholar 

  • Jeong JY, Choi JW, Jeon KI, Jue DM (2002) Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells. Immunology 105:83–91

    Article  PubMed  Google Scholar 

  • Jessop S, Whitelaw D, Jordaan F (2004) Drugs for discoid lupus erythematosus (Cochrane Review). In: The Cochrane Library, Issue 2, Chichester, UK, Y. Wiley & Sons Ltd.

    Google Scholar 

  • Jewell ML, McCauliffe DP (2000) Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 42:983–987

    Article  PubMed  Google Scholar 

  • Johansen PB, Gran JT (1998) Ototoxicity due to hydroxychloroquine: report of two cases. Clin Exp Rheumatol 16:472–474

    PubMed  Google Scholar 

  • Jones SK (1999) Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol 140:3–7

    Article  PubMed  Google Scholar 

  • Jordan P, Brookes JG, Nikolic G, Le Couteur DG (1999) Hydroxychloroquine overdose: toxicokinetics and management. J Toxicol Clin Toxicol 37:861–864

    Article  PubMed  Google Scholar 

  • Khoury H, Trinkaus K, Zhang MJ, Adkins D, Brown R, Vij R, Goodnough LT, Ma MK, McLeod HL, Shenoy S, Horowitz M, Dispersio JF (2003) Hydroxychloroquine for the prevention of acute graft-versushost disease after unrelated donor transplantation. Biol Blood Marrow Transplant 9:714–721

    Article  PubMed  Google Scholar 

  • Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, Koren G, Ito S, Buncic RJ (2001) Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 358:813–814

    Article  PubMed  Google Scholar 

  • Krishna S, White NJ (1996) Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokin 30:263–299

    Google Scholar 

  • Kuhn A, Richter-Hintz D, Oslislo C, Ruzicka T, Megahed M, Lehmann P (2000) Lupus erythematosus tumidus — a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 136:1033–1041

    PubMed  Google Scholar 

  • Laaksonen AL, Koskiahde V, Juva K (1974) Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatol 3:103–109

    PubMed  Google Scholar 

  • Leigh JM, Kennedy CTC, Ramsey JD, Henderson WJ (1979) Mepacrine pigmentation in systemic lupus erythematosus. Br J Dermatol 101:147–153

    PubMed  Google Scholar 

  • Levy GD, Munz SJ, Paschal J (1997) Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicentre outpatient practice. Arthritis Rheum 40:1482–1486

    PubMed  Google Scholar 

  • Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JL, Tura BR, Albuquerque EM, Jesus NR (2001) Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10:401–404

    Article  PubMed  Google Scholar 

  • Liu ST, Wang CR, Yin GD, Liu MF, Lee GL, Chen MY, Chuang CY, Chen CY (2001) Hydroxychloroquine sulphate inhibits in vitro apoptosis of circulating lymphocytes in patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol 19:29–35

    PubMed  Google Scholar 

  • Loudon JR (1988) Hydroxychloroquine and postoperative thromboembolism after total hip replacement. Amer J Med 85(Suppl 4a):57–61

    Article  Google Scholar 

  • Mackenzie AH (1983) Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 75(Suppl):40–45

    Article  Google Scholar 

  • Makin AJ, Wendon J, Fitt S, Portmann BC, Williams R (1994) Fulminant hepatic failure secondary to hydroxychloroquine. Gut 35:569–570

    PubMed  Google Scholar 

  • Maksymowych W, Russell AS (1987) Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 16:206–221

    Article  PubMed  Google Scholar 

  • Malcangi G, Fraticelli P, Palmieri C, Cappelli M, Danieli MG (2000) Hydroxychloroquine-induced seizure in a patient with systemic lupus erythematosus. Rheumatol Int 20:31–33

    Article  PubMed  Google Scholar 

  • Marquardt K, Albertson TE (2001) Treatment of hydroxychloroquine overdose. Am J Emerg Med 19:420–424

    Article  PubMed  Google Scholar 

  • Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M (2003) The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reapparaisal. Ophthalmology 110:1321–1326

    Article  PubMed  Google Scholar 

  • McDuffie FC (1965) Bone marrow depression after drug therapy in patients with systemic lupus erythematosus. Ann Rheum Dis 24:289–292

    PubMed  Google Scholar 

  • Meinao IM, Sato EI, Andrade LE, Ferraz MB, Atra E (1996) Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 5:237–241

    PubMed  Google Scholar 

  • Metayer I, Balguerie X, Courville P, Lauret P, Joly P (2001) Photodermatosis induced by hydroxychloroquine: 4 cases. Ann Dermatol Venereol 128:729–731

    PubMed  Google Scholar 

  • Miller DR, Fiechtner JJ, Carpenter JR, Brown RR, Stroshane RM, Stecher VJ (1987) Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. Arthritis Rheum 30:567–571

    PubMed  Google Scholar 

  • Minzi OM, Rais M, Svensson JO, Gustafsson LL, Ericsson O (2003) High-performance liquid chromatographic method for determination of amodiaquine, chloroquine and their monodesethyl metabolites in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 783:473–480

    PubMed  Google Scholar 

  • Mitja K, Izidor K, Music E (2000) Chloroquine-induced drug hypersensitivity alveolitis. Pneumologie 54:395–397

    Article  PubMed  Google Scholar 

  • Molad Y, Gorshtein A, Wysenbeek AJ, Guedj D, Majadla R, Weinberger A, Amit-Vazina M (2002) Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 11:356–361

    Article  PubMed  Google Scholar 

  • Morgan KW, Callen JP (2001) Calcifying lupus panniculitis in a patient with subacute cutaneous lupus erythematosus: response to diltiazem and chloroquine. J Rheumatol 28:2129–2132

    PubMed  Google Scholar 

  • Murphy M, Carmichael AJ (2001) Fatal toxic epidermal necrolysis associated with hydroxychloroquine. Clin Exp Dermatol 26:457–458

    Article  PubMed  Google Scholar 

  • Nguyen K, Washenik K, Shupack J (2002) Necrobiosis lipoidica diabeticorum treated with chloroquine. J Am Acad Dermatol 45:S34–36

    Article  Google Scholar 

  • [No authors listed] (1995) A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Amer J Med 98:156–168

    Google Scholar 

  • Nord JE, Shah PK, Rinaldi RZ, Weisman MH (2004) Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum 33:336–351

    Article  PubMed  Google Scholar 

  • Ochsendorf FR, Runne U(1991) Chloroquin und Hydroxychloroquin: Nebenwirkungsprofil wichtiger Therapeutika. Hautarzt 42:140–146

    PubMed  Google Scholar 

  • Ochsendorf FR, Runne U (1991) Subakute Chloroquin-Ãœberdosierung: Schwindel, körperliche Schwäche, bullöse Lichtreaktion, Sehstörungen und generalisierte Weißfärbung der Haare. Dtsch med Wschr 116:1513–1516

    PubMed  Google Scholar 

  • Ochsendorf FR, Runne U, Goerz G, Zrenner E (1993) Chloroquin-Retinopathie: durch individuelle Tagesdosis vermeidbar. Dtsch Med Wochenschr 118:1895–1898

    PubMed  Google Scholar 

  • Ochsendorf FR, Runne U (1997) Therapie des systemischen Lupus erythematodes. Dtsch Med Wochenschr 122:877

    PubMed  Google Scholar 

  • O’Dell JC, Haire C, Erikson N, Drymalski W, Palmer W, Eckhoff J, Garwood V, Maloley P, Klassen L, Wees S, Klein H, Moore G (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine or a combination of all three medications. New Engl J Med 344:1287–1291

    Article  Google Scholar 

  • O’Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebocontrolled trial. Arthritis Rheum 46:1164–1170

    Article  PubMed  Google Scholar 

  • Onigbogi O, Ajayi AA, Ukponmwan OE (2000) Mechanisms of chloroquine-induced body-scratching behavior in rats: evidence of involvement of endogenous opioid peptides. Pharmacol Biochem Behav 65:333–337

    Article  PubMed  Google Scholar 

  • Onyeji CO, Ogunbona FA (2001) Pharmacokinetic aspects of chloroquine-induced pruritus: influence of dose and evidence for varied extent of metabolism of the drug. Eur J Pharm Sci 13:195–201

    PubMed  Google Scholar 

  • Orteu CH, Buchanan JA, Hutchison I, Leigh IM, Bull RH (2001) Systemic lupus erythematosus presenting with oral mucosal lesions: easily missed? Br J Dermatol 144:1219–1223

    PubMed  Google Scholar 

  • Ostensen M, Ramsey-Goldman R (1998) Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Drug Saf 19:389–410

    PubMed  Google Scholar 

  • Parke AL, West B (1996) Hydroxychloroquine in pregnant patients with SLE. J Rheumatol 23:1715–1718

    PubMed  Google Scholar 

  • Petri M (1996) Hydroxychloroquine use in the Baltimore lupus cohort. Effects on lipids, glucose and thrombosis. Lupus 5(Suppl 1):S16–S22

    PubMed  Google Scholar 

  • Pinckers A, Broekhuyse RM (1983) The EOG in rheumatoid arthritis. Acta Ophthalmol 61:831–837

    Google Scholar 

  • Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN (1999) The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 26:325–330

    PubMed  Google Scholar 

  • Reeves GE, Boyle MJ, Bonfield J, Dobson P, Loewenthal M (2004) Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 34:182–186

    PubMed  Google Scholar 

  • Reuss-Borst M, Berner B, Wulf G, Muller GA (1999) Complete heart block as a rare complication of treatment with chloroquine. J Rheumatol 26:1394–1395

    PubMed  Google Scholar 

  • Rigaudiere F, Ingster-Moati I, Hache JC, Leid J, Verdet R, Haymann P, Rigolet MH, Zanlonghi X, Defoort S, Le Gargasson JF (2004) Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment. J Fr Ophthalmol 27:191–199

    Google Scholar 

  • Ruiz-Irastorza G, Khamashta MA, Hughes GR (2000) Therapy of systemic lupus erythematosus: new agents and new evidence. Expert Opin Investig Drugs 9:1581–1593

    PubMed  Google Scholar 

  • Runne U, Ochsendorf FR, Schmid K, Raudonat HW (1992) Sequential concentration of chloroquine in human hair correlates with ingested dose and duration of therapy. Acta Derm Venereol (Stockh) 72:355–357

    PubMed  Google Scholar 

  • Savarino A, Gennero L, Sperber K, Boelaert JR (2001) The anti-HIV-1 activity of chloroquine. J Clin Virol 20:131–135

    Article  PubMed  Google Scholar 

  • Scherbel AL, Mackenzie AH, Nousek JE, Adtjian M (1965) Ocular Lesions in Rheumatoid Arthritis and Related Disorders with Particular Reference to Retinopathy. N Engl J Med 273: 360–366

    Google Scholar 

  • Sontheimer RD (2000) Questions answered and a $1 million question raised concerning lupus erythematosus tumidus: is routine laboratory surveillance testing during treatment with hydroxychloroquine for skin disease really necessary. Arch Dermatol 136:1044–1049

    Article  PubMed  Google Scholar 

  • Stein M, Bell MJ, Ang LC (2000) Hydroxychloroquine neuromyotoxicity. J Rheumatol 27: 2927–2931

    PubMed  Google Scholar 

  • Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB (2000) Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 27:2142–2145

    PubMed  Google Scholar 

  • Tett SE, McLachlan AJ, Cutler DJ, Day RO (1994) Pharmacokinetics and pharmacodynamis of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate. Chirality 6:355–359

    Article  PubMed  Google Scholar 

  • Toubi E, Rosner I, Rozenbaum M, Kessel A, Golan TD (2000) The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 9:92–95

    Article  PubMed  Google Scholar 

  • Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cidicino A, Danoff D, Osterland CK, Yeadon C, Smith CD (1998) A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian hydroxychloroquine study group. Lupus 7:80–85

    Article  PubMed  Google Scholar 

  • Urowitz M, Gladman D, Bruce I (2000) Atherosclerosis and systemic lupus erythematosus. Curr Rheumatol Rep 2:19–23

    PubMed  Google Scholar 

  • Versapuech J, Beylot-Barry M, Doutre MS, Beylot C (2000) Subacute cutaneous lupus. Evolutive and therapeutic features of a series of 24 cases. Presse Med 29:1596–1599

    PubMed  Google Scholar 

  • von Schmiedeberg S, Ronnau AC, Schuppe HC, Specker C, Ruzicka T, Lehmann P (2000) Combination of antimalarial drugs mepacrine and chloroquine in therapy refractory cutaneous lupus erythematosus. Hautarzt 51:82–85

    Article  PubMed  Google Scholar 

  • Walker O, Ademowo OG (1996) A rapid, cost-effective liquid-chromatographic method for the determination for chloroquine and desethylchloroquine in biological fluids. Therap Drug Monitor 1:92–96

    Article  Google Scholar 

  • Wallace DJ (1989) The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum 18:282–296

    Article  PubMed  Google Scholar 

  • Wallace DJ, Linker-Israeli M, Methger AL, Stecher VM (1993) The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 2(Suppl 1):S13–S15

    PubMed  Google Scholar 

  • Wallace DJ (1996) The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 5(Suppl 1):S59–S64

    PubMed  Google Scholar 

  • Wallace DJ (2000) Is there a role for quinacrine (Atabrine) in the new millennium? Lupus 9:81–82

    Article  PubMed  Google Scholar 

  • Weber F, Schmuth M, Fritsch P, Sepp N (2001) Lymphocytic infiltration of the skin is a photosensitive variant of lupus erythematosus: evidence by phototesting. Br J Dermatol 144:292–296

    Article  PubMed  Google Scholar 

  • Wechsler B, Le Thi Huong D, Piette JC (1999) Pregnancy and systemic lupus erythematosus. Ann Med Interne (Paris) 150:408–418

    Google Scholar 

  • Williams HJ, Egger MJ, Szinger JZ, Willkens RF, Kalunian KC, Clegg DO, Skosey JL, Brooks RH, Alarcon GS, Steen VD, Polisson RP, Ward JR (1994) Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol 21:1457–1462

    PubMed  Google Scholar 

  • Wollheim FA, Hanson A, Laurell CB (1978) Chloroquine treatment in rheumatoid arthritis. Scand J Rheumatol 7:171–176

    PubMed  Google Scholar 

  • Zeidler GS (1995) Chloroquin (ResochinR) Synoptische Darstellung eines Pharmakons und seiner Indikation in der Medizin, speziell in der Dermatologie. In: Hautklinik. Düsseldorf: Heinrich-Heine University, Inaugural Dissertation

    Google Scholar 

  • Ziering CL, Rabinowith LG, Esterly NB (1993) Antimalarials for children: indications, toxicities, and guidelines. J Am Acad Dermatol 28:764–770

    PubMed  Google Scholar 

Download references

Authors
  1. Falk R. Ochsendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hautklinik, Universitätsklinikum Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany

    Annegret Kuhn  & Thomas Ruzicka  & 

  2. HELIOS Klinikum Wuppertal Klinik für Dermatologie, Allergologie und Umweltmedizin, Universitätsklinikum Witten-Herdecke, Arrenbergerstraße 20, 42117, Wuppertal, Germany

    Percy Lehmann

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin · Heidelberg

About this chapter

Cite this chapter

Ochsendorf, F.R. (2005). Antimalarials. In: Kuhn, A., Lehmann, P., Ruzicka, T. (eds) Cutaneous Lupus Erythematosus. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26581-3_26

Download citation

  • DOI: https://doi.org/10.1007/3-540-26581-3_26

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-44266-0

  • Online ISBN: 978-3-540-26581-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation